rucaparib (rubraca) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer. Rucaparib is being investigated in clinical trials against prostate cancer, breast cancer and other neoplasms.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$96.0387 - $116.2737
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ag014699 | ag 014699 | ag-014699 | ag-14447 | ag-14699 | pf-01367338 | rubraca | rucaparib | rucaparib camsylate | rucaparib phosphate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue